STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3789 by analyst upside · 2026-08-14
CRNX
Crinetics Pharmaceuticals, Inc.
Healthcare · Market Cap $9B · P/E 0x
ANALYST PRICE TARGET
+1.3%
implied upside to consensus target
Current Price $84.44
Consensus Target $85.5
Bull Target $90.0
Bear Target $85.0
Analysts Covering 10
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
1
Hold
9
Sell
0
52-Week Low $28.73
52-Week High $84.71
YTD Return +80.7%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-5.05
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $42M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $28.73
52-Week High $84.71
Current Price $84.44
Bear Target $85.0
Bull Target $90.0
● Now $84.44 ● Target $85.5
TRADING DATA
Avg Volume 3.8M
YTD Return +80.7%
Analyst Count 10
Consensus Hold
Upside to Target +1.3%
Last Updated 2026-08-14

ANALYST SUMMARY

Crinetics Pharmaceuticals, Inc. (CRNX) is currently trading at $84.44 with a Wall Street consensus price target of $85.5, implying potential upside of 1.3% over the next 12 months. 10 analysts currently cover CRNX, with a consensus rating of Hold - 10% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $90.0, while the most cautious has a target of $85.0.

CRNX operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 80.7% year-to-date and is currently trading near the upper end of its 52-week range of $28.73 – $84.71.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CRNX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-15 31% win rate (48 calls)
Citizens reit
Market Outperform → Market Outperform 2026-06-11 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-05-15 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-05-11 14% win rate (7 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-08 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-04-28 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-03-02 Building track record
Goldman Sachs ↑ Upgrade
Neutral → Buy 2026-01-12 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
18/30
Consensus clarity
29/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →